NDC 0069-0249

Ruxience

Rituximab-pvvr

Ruxience is a Intravenous Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Pfizer Laboratories Div Pfizer Inc. The primary component is Rituximab.

• Product ID: 0069-0249_51df4093-b8e1-4708-b3d0-627ee7086f18
• NDC: 0069-0249
• Product Type: Human Prescription Drug
• Proprietary Name: Ruxience
• Generic Name: Rituximab-pvvr
• Dosage Form: Injection, Solution
• Route of Administration: INTRAVENOUS
• Marketing Start Date: 2020-01-23
• Marketing Category: BLA / BLA
• Application Number: BLA761103
• Labeler Name: Pfizer Laboratories Div Pfizer Inc
• Substance Name: RITUXIMAB
• Active Ingredient Strength: 500 mg/50mL
• Pharm Classes: CD20-directed Antibody Interactions [MoA],CD20-directed Cytolytic Antibody [EPC]
• NDC Exclude Flag: N
• Listing Certified Through: 2022-12-31

Packaging

NDC 0069-0249-01

1 VIAL, SINGLE-USE in 1 CARTON (0069-0249-01) > 50 mL in 1 VIAL, SINGLE-USE

• Marketing Start Date: 2020-01-23
• NDC Exclude Flag: N
• Sample Package?: N

NDC SPL Data Element Entries

NDC 0069-0249-01 [00069024901]

Ruxience INJECTION, SOLUTION

• Marketing Category: BLA
• Application Number: BLA761103
• Product Type: HUMAN PRESCRIPTION DRUG
• Billing Unit: ML
• Marketing Start Date: 2020-01-23

Drug Details

Active Ingredients

Ingredient	Strength
RITUXIMAB	500 mg/50mL

Pharmacological Class

• CD20-directed Antibody Interactions [MoA]
• CD20-directed Cytolytic Antibody [EPC]

NDC Crossover Matching brand name "Ruxience" or generic name "Rituximab-pvvr"

NDC	Brand Name	Generic Name
0069-0238	Ruxience	rituximab-pvvr
0069-0249	Ruxience	rituximab-pvvr